Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).

18 total trials none currently recruiting 18 completed early-phase tilt top decile by trial count

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): 18 sponsored US clinical trials, none currently recruiting.

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 18 completed. 2 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 1 trials.

Top-decile sponsor footprint

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

18 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

18 total, page 1 of 1

COMPLETED Phase 1

A Phase 1, Open-Label, 10 Day Safety Study

NCT01623401
COMPLETED Phase 1

A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

NCT01577459
COMPLETED Phase 2

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

NCT01519778
COMPLETED Phase 1

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

NCT01539473
COMPLETED Phase 1

Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

NCT01496677
COMPLETED Phase 1

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

NCT01461460
COMPLETED Phase 1

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

NCT01452828
COMPLETED Phase 3

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01421511
COMPLETED Phase 1

A PK and Safety Study in Subjects With Hepatic Impairment

NCT01431833
COMPLETED Phase 1

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

NCT01271998
COMPLETED Phase 1

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

NCT01442831
COMPLETED Phase 3

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

NCT01170221
COMPLETED Phase 1

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
COMPLETED Phase 1

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

NCT00876655
COMPLETED Phase 2

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

NCT00761215
COMPLETED Phase 1

Microdialysis and Pharmacokinetic Study of TR-701

NCT00666601
COMPLETED Phase 1

Food Effects of Single Oral Dose of 600mg TR-701

NCT00671359
COMPLETED Phase 1

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

NCT00671814

Phase Distribution

PhaseTrial count
Phase 1 14
Phase 2 2
Phase 3 2

Therapeutic Areas

Healthy Subjects 1

How the Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) early-phase archive is shaped

18 indexed studies, none listed as recruiting (0% open); 18 completed (100%).

Phase mix: 2 late (III/IV) vs 16 early (I/II) (early-phase heavy).

Top condition: Healthy Subjects (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): archived-pipeline peers nationwide

Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)ADC Therapeutics S.A.Akros PharmaAO Clinical Investigation and Publishing DocumentationAO Innovation Translation Center10xBio22nd Century Group23andMe3-C Institute for Social Development
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 18 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) page

18 registered trials is a research-attention snapshot, not an endorsement of Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) or any single study.

  • None of Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy Subjects is the condition Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline card: 18 registered trials from official public datasets.Report a data error.